Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Point and Figure Charting -- Ignore unavailable to you. Want to Upgrade?

To: Ms. X who wrote (11247)	12/9/1998 9:34:00 PM
From: Jerry Olson	Respond to of 34816

Hey Janie... there's a chart already??? WOW!!! so much professionalism...gee... i'm lookin to buy it...<g>... the resident net/nut...

To: Ms. X who wrote (11247)	12/10/1998 8:47:00 AM
From: Mr.Manners	Read Replies (1) \| Respond to of 34816

Hi Jan, usually their weakest... SOURCE: Zila, Inc. Zila Reports Profitable First Quarter PHOENIX, Dec. 10 /PRNewswire/ -- Zila, Inc. (Nasdaq: ZILA - news), international provider of healthcare products for dental/medical professionals and consumers, announced revenues of $16,503,000 and net income of $0.02 per share for the first quarter of fiscal year 1999 (period ending October 31, 1998). This was in contrast to FY 1998 first quarter revenues of $10,800,000 and a loss per share of $0.01. Net income in the first quarter of FY 1999 was $756,000, compared to a net loss of $430,000 in the year-ago quarter. The Company maintained a strong balance sheet, with insignificant long-term debt. Zila's current ratio is a healthy 3.5 to 1. These results were achieved while the Company continued to invest heavily in the OraTest® oral cancer detection product and in other R&D programs throughout the Company. A total of $757,700 domestic and international OraTest program costs were expensed, including R&D, manufacturing, marketing and regulatory items. Also expensed were $325,000 in research and product development costs related to several of Zila's other products, as well as $578,400 of goodwill amortization related to acquisitions. Included in net income was an income tax benefit of $596,000, resulting from the utilization of net operating losses carried forward. Zila President Joseph Hines noted, ''Due to product delivery delays, significant revenue and resulting income was deferred from the first quarter into the second in two of our divisions. While we are pleased with first quarter financial results, they clearly would have been much better had we not encountered these delays. The full fiscal year outlook remains very positive.'' Zila reported earlier that the FDA accepted the OraTest New Drug Application on September 3, 1998, and assigned it ''priority review'' status, which targets completion of agency review within six months. The OraTest product will be reviewed by the FDA Oncologic Drugs Advisory Committee at a hearing on January 13, 1999. Dr. Ralph Green, President of Zila Biomedical, said, ''We expect the committee will recommend approval of our inexpensive and potentially life-saving technology. Preparation for domestic marketing is fully underway.''